title: Effects of ibuprofen and indomethacin on urinary antidiuretic hormone excretion in preterm infants treated for patent ductus arteriosus.
abstract: OBJECTIVE
  To compare the effects of intravenous ibuprofen and indomethacin for treatment of patent ductus arteriosus (PDA) on urinary antidiuretic hormone (ADH) excretion, as a cause of oliguria.
  
  
  METHODS
  Forty-four respiratory distress syndrome prematures (<or=34 weeks' gestation) with PDA received either ibuprofen (n = 22) in an initial dose of 10 mg/kg followed by two doses of 5 mg/kg each after 24 and 48 h or three doses at 12-hour intervals of indomethacin (n = 24), 0.2 mg/kg, both infused continuously over a period of 15 min. Urinary ADH excretion, diuresis, serum creatinine, urinary sodium, fractional excretion of sodium, and urinary osmolality were measured before and after treatment.
  
  
  RESULTS
  Indomethacin treatment caused a significant decrease in urinary ADH excretion (21.8 +/- 20.8 vs. 13.8 +/- 12.9 pg/ml; p < 0.05), along with a significant reduction in urinary sodium (92.1 +/- 36.1 vs. 64.8 +/- 35.6; p < 0.05), fractional excretion of sodium (68.5 +/- 37.1 vs. 45.6 +/- 37.1; p < 0.05), and urinary osmolality (276.2 +/- 103.9 vs. 226.4 +/- 60.3; p < 0.05). Ibuprofen treatment did not modify urinary ADH excretion and caused a statistically insignificant decrease in urinary sodium and in fractional excretion of sodium.
  
  
  CONCLUSIONS
  Compared with ibuprofen, indomethacin caused a significant reduction in urinary ADH excretion and a significant decrease in urinary sodium and osmolality.
authors.affiliation: Pediatrics Department, Padua University School of Medicine, Padua, Italy. zanardo@pediatria.unipd.it
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Zanardo
authors.forename: Stefania
authors.initials: S
authors.lastname: Vedovato
authors.forename: Paola
authors.initials: P
authors.lastname: Lago
authors.forename: Daniele
authors.initials: D
authors.lastname: Piva
authors.forename: Diego
authors.initials: D
authors.lastname: Faggian
authors.forename: Laura
authors.initials: L
authors.lastname: Chiozza
mesh_terms: D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D004374:Ductus Arteriosus, Patent / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007052:Ibuprofen / Q000009:adverse effects* / Q000494:pharmacology; D007213:Indomethacin / Q000009:adverse effects* / Q000494:pharmacology; D007231:Infant, Newborn; D007234:Infant, Premature; D009846:Oliguria / Q000139:chemically induced*; D012127:Respiratory Distress Syndrome, Newborn / Q000209:etiology; D014667:Vasopressins / Q000378:metabolism* / Q000652:urine
chemical_list: D016861:Cyclooxygenase Inhibitors; D014667:Vasopressins; D007052:Ibuprofen; D007213:Indomethacin